Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12407095 | 0.83 | MRGPRX1 (0.51) | KMT2AMRGPRX1HRH1 | |
| SCHEMBL14468058 | 0.83 | L3MBTL1 (0.46) | FKBP1AMEN1KMT2AMAPTMRGPRX1 | |
| SCHEMBL19050657 | 0.81 | MEN1 (0.47) | FKBP1AMEN1KMT2AMRGPRX1BRD4 | |
| SCHEMBL2760280 | 0.80 | FKBP1A (0.56) | FKBP1AMEN1KMT2AMAPTFFAR4 | |
| SCHEMBL10270716 | 0.79 | ALDH1A1 (0.47) | MRGPRX1ALDH1A1 | |
| SCHEMBL11561858 | 0.78 | FKBP1A (0.54) | FKBP1AMEN1KMT2AMAPTFFAR4 | |
| SCHEMBL29686668 | 0.75 | TSHR (0.47) | MAPTMRGPRX1BRD4PKMMAPK1 | |
| SCHEMBL14513158 | 0.75 | BRD4 (0.50) | FKBP1AMEN1KMT2ABRD4ALDH1A1 | |
| SCHEMBL26118836 | 0.75 | TSHR (0.47) | MAPTMRGPRX1BRD4PKMMAPK1 | |
| SCHEMBL11723641 | 0.74 | MRGPRX1 (0.42) | MRGPRX1HRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | FKBP1A 684/4885MEN1 4800/4885KMT2A 4464/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | FKBP1A 684/4885MEN1 4800/4885KMT2A 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.